S&P 500   3,299.36 (-0.49%)
DOW   27,250.28 (-0.14%)
QQQ   269.63 (-1.05%)
AAPL   110.61 (-1.07%)
MSFT   205.43 (-0.96%)
FB   255.47 (+0.28%)
GOOGL   1,440.33 (-1.34%)
AMZN   3,077.40 (-1.65%)
NVDA   502.46 (-0.60%)
TSLA   399.24 (-5.89%)
BABA   275.77 (+0.17%)
CGC   15.12 (-5.74%)
GE   6.39 (+2.24%)
MU   50.82 (+2.25%)
AMD   76.83 (-1.12%)
T   28.50 (-0.04%)
F   6.82 (+0.59%)
ACB   5.62 (-23.22%)
GILD   63.64 (+0.38%)
NFLX   483.04 (-1.66%)
DIS   125.91 (-1.02%)
BAC   24.07 (+0.54%)
BA   158.23 (+0.91%)
S&P 500   3,299.36 (-0.49%)
DOW   27,250.28 (-0.14%)
QQQ   269.63 (-1.05%)
AAPL   110.61 (-1.07%)
MSFT   205.43 (-0.96%)
FB   255.47 (+0.28%)
GOOGL   1,440.33 (-1.34%)
AMZN   3,077.40 (-1.65%)
NVDA   502.46 (-0.60%)
TSLA   399.24 (-5.89%)
BABA   275.77 (+0.17%)
CGC   15.12 (-5.74%)
GE   6.39 (+2.24%)
MU   50.82 (+2.25%)
AMD   76.83 (-1.12%)
T   28.50 (-0.04%)
F   6.82 (+0.59%)
ACB   5.62 (-23.22%)
GILD   63.64 (+0.38%)
NFLX   483.04 (-1.66%)
DIS   125.91 (-1.02%)
BAC   24.07 (+0.54%)
BA   158.23 (+0.91%)
S&P 500   3,299.36 (-0.49%)
DOW   27,250.28 (-0.14%)
QQQ   269.63 (-1.05%)
AAPL   110.61 (-1.07%)
MSFT   205.43 (-0.96%)
FB   255.47 (+0.28%)
GOOGL   1,440.33 (-1.34%)
AMZN   3,077.40 (-1.65%)
NVDA   502.46 (-0.60%)
TSLA   399.24 (-5.89%)
BABA   275.77 (+0.17%)
CGC   15.12 (-5.74%)
GE   6.39 (+2.24%)
MU   50.82 (+2.25%)
AMD   76.83 (-1.12%)
T   28.50 (-0.04%)
F   6.82 (+0.59%)
ACB   5.62 (-23.22%)
GILD   63.64 (+0.38%)
NFLX   483.04 (-1.66%)
DIS   125.91 (-1.02%)
BAC   24.07 (+0.54%)
BA   158.23 (+0.91%)
S&P 500   3,299.36 (-0.49%)
DOW   27,250.28 (-0.14%)
QQQ   269.63 (-1.05%)
AAPL   110.61 (-1.07%)
MSFT   205.43 (-0.96%)
FB   255.47 (+0.28%)
GOOGL   1,440.33 (-1.34%)
AMZN   3,077.40 (-1.65%)
NVDA   502.46 (-0.60%)
TSLA   399.24 (-5.89%)
BABA   275.77 (+0.17%)
CGC   15.12 (-5.74%)
GE   6.39 (+2.24%)
MU   50.82 (+2.25%)
AMD   76.83 (-1.12%)
T   28.50 (-0.04%)
F   6.82 (+0.59%)
ACB   5.62 (-23.22%)
GILD   63.64 (+0.38%)
NFLX   483.04 (-1.66%)
DIS   125.91 (-1.02%)
BAC   24.07 (+0.54%)
BA   158.23 (+0.91%)
Log in
LON:ARIX

Arix Bioscience Share Forecast, Price & News

GBX 103
-1.50 (-1.44 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
101
Now: GBX 103
107.02
50-Day Range
74.50
MA: GBX 83.71
106
52-Week Range
57
Now: GBX 103
122
Volume12,141 shs
Average Volume111,643 shs
Market Capitalization£139.68 million
P/E Ratio7.36
Dividend YieldN/A
BetaN/A
Arix Bioscience plc, formerly known as Perceptive Bioscience Investments Limited, is a venture capital firm specializing in seed, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is based in London, United Kingdom with an additional office in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.84 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-72901050

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£23.47 million
Cash FlowGBX 32.75 per share
Book ValueGBX 192.40 per share

Profitability

Miscellaneous

Employees14
Market Cap£139.68 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 103
-1.50 (-1.44 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARIX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARIX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arix Bioscience (LON:ARIX) Frequently Asked Questions

How has Arix Bioscience's stock price been impacted by COVID-19?

Arix Bioscience's stock was trading at GBX 77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARIX shares have increased by 33.8% and is now trading at GBX 103.
View which stocks have been most impacted by COVID-19
.

Who are some of Arix Bioscience's key competitors?

Who are Arix Bioscience's key executives?

Arix Bioscience's management team includes the following people:
  • Dr. Joseph Anderson, CEO & Co-Founder (Age 60)
  • Mr. James Hedley Rawlingson, Chief Financial Officer (Age 51)
  • Sir Christopher Thomas Evans, Consultant (Age 62)
  • Mr. Robert Lyne, COO, Gen. Counsel & Company Sec.
  • Ms. Charlotte Parry, Head of Investor Relations

What is Arix Bioscience's stock symbol?

Arix Bioscience trades on the London Stock Exchange (LON) under the ticker symbol "ARIX."

How do I buy shares of Arix Bioscience?

Shares of ARIX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Arix Bioscience's stock price today?

One share of ARIX stock can currently be purchased for approximately GBX 103.

How big of a company is Arix Bioscience?

Arix Bioscience has a market capitalization of £139.68 million and generates £23.47 million in revenue each year. Arix Bioscience employs 14 workers across the globe.

What is Arix Bioscience's official website?

The official website for Arix Bioscience is arixbioscience.com.

How can I contact Arix Bioscience?

Arix Bioscience's mailing address is 20 Berkeley Square, LONDON, W1J 6EQ, United Kingdom. The company can be reached via phone at +44-20-72901050.

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.